List of Excipients in Branded Drug GLYCOPYRROLATE ORAL SOLUTION

« Back to Dashboard

Generic Drugs Containing GLYCOPYRROLATE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Granules Pharmaceuticals Inc	glycopyrrolate	70010-106	ANHYDROUS CITRIC ACID
Granules Pharmaceuticals Inc	glycopyrrolate	70010-106	GLYCERIN
Granules Pharmaceuticals Inc	glycopyrrolate	70010-106	METHYLPARABEN

What are the Most Frequently-Used Excipients in GLYCOPYRROLATE ORAL SOLUTION?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
2	GLYCERIN
2	METHYLPARABEN

Glycopyrrolate Oral Solution Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Glycopyrrolate oral solution is a small-molecule pediatric product with formulation-driven commercial opportunities. The strongest opportunities are dose-measurement accuracy, palatability, preservative tolerance, low-volume dosing, supply-chain resilience, and differentiated formulations for patients with neurologic impairment. The reference product, Cuvposa, is an oral solution containing glycopyrrolate 1 mg/5 mL for chronic severe drooling in pediatric patients aged 3 to 16 years [1].

What is the FDA status of glycopyrrolate oral solution?

Glycopyrrolate oral solution is an FDA-approved prescription product. Cuvposa was approved under NDA 022571 in 2010 for chronic severe drooling associated with neurologic conditions, including cerebral palsy, in pediatric patients aged 3 to 16 years [1,2].

Regulatory item	Glycopyrrolate oral solution
Active ingredient	Glycopyrrolate
Dosage form	Oral solution
Common strength	1 mg/5 mL
Reference product	Cuvposa
Reference sponsor	Shionogi Inc.
Original FDA approval	2010
Approved population	Pediatric patients 3 to 16 years
Main indication	Chronic severe drooling
FDA pathway for competitors	ANDA or applicable 505(b)(2) pathway
Biosimilar pathway	Not applicable
Core regulatory issue	Demonstrating pharmaceutical equivalence and bioequivalence, or establishing a justified alternative formulation

Cuvposa is a quaternary ammonium anticholinergic. Its limited penetration across the blood-brain barrier is relevant to the product’s clinical positioning, although systemic anticholinergic adverse effects remain important, including dry mouth, constipation, urinary retention, blurred vision, tachycardia and reduced sweating [1].

What excipients are used in glycopyrrolate oral solution?

The commercial excipient profile is designed around aqueous stability, taste masking, microbial control and pediatric acceptability. Public labeling identifies excipients that include acidifying and buffering agents, sweeteners, preservatives, flavoring and purified water. Exact composition can vary by manufacturer and approved product label.

Reference formulation characteristics

Cuvposa labeling identifies the following formulation functions:

Excipient function	Relevant excipient classes	Commercial purpose
Vehicle	Purified water	Dissolves glycopyrrolate and supports liquid dosing
pH control	Citric acid, sodium citrate	Stabilizes pH and supports chemical stability
Sweetening	Sucralose or equivalent high-intensity sweetener	Masks bitter or medicinal taste without adding substantial sugar
Flavoring	Pediatric flavor system	Improves acceptance and adherence
Preservation	Methylparaben, potassium sorbate or comparable system	Controls microbial growth during multidose use
Tonicity and mouthfeel	Polyols or other compatible agents, where used	Modifies viscosity, taste and oral sensory profile

The excipient list must be taken from the current product-specific labeling because generic products can use different inactive ingredients. FDA labeling and DailyMed are the primary sources for the marketed composition [1,3].

Which excipient properties matter most for glycopyrrolate oral solution?

The highest-value excipient decisions relate to stability, taste, preservative performance and dosing accuracy.

pH and chemical stability

Glycopyrrolate oral solution requires a controlled pH environment. Citrate buffering is commercially attractive because it is familiar to regulators, broadly available and suitable for oral liquids. Excessive buffer strength can increase taste impact and may affect tolerability in patients with oral sensitivity.

A formulation program should evaluate:

• Glycopyrrolate assay and related substances across the intended shelf life
• pH drift after opening
• Compatibility with flavor and preservative systems
• Stability in bottles, oral syringes and dosing cups
• Light exposure and elevated-temperature degradation
• Microbial robustness after repeated patient use

Taste masking

Taste is a major commercial differentiator. Children with neurologic impairment may have feeding difficulties, dysphagia or sensory aversion. A strong flavor system can improve adherence, but excessive flavor intensity can reduce acceptance.

Potential approaches include:

• Sucralose-based sweetness
• Sugar-free fruit flavors
• Low-acid flavor systems
• Controlled use of polyols
• Taste-modifying agents compatible with pediatric use
• Coacervate or microencapsulation approaches, if technically justified

Glycopyrrolate is administered in small liquid volumes, so taste masking can often be optimized without substantially increasing viscosity. The formulation must avoid excipients that create aspiration, gastrointestinal or dental concerns in the target population.

Preservative selection

Multidose oral solutions require a microbial-control strategy. Preservatives can create safety, tolerability and regulatory constraints, particularly in chronic pediatric use.

Key considerations include:

• Preservative efficacy testing under USP <51>
• Performance across the labeled pH range
• Compatibility with container closure systems
• Exposure in young children receiving repeated daily doses
• Potential sensitivity to parabens, sorbate systems or flavor components
• In-use stability after opening

A preservative-free formulation could support premium positioning, but it would require a credible alternative such as unit-dose packaging, a sterile manufacturing approach where justified, or a validated antimicrobial container system. The added packaging cost could outweigh the commercial benefit unless the product targets patients with preservative intolerance or institutional settings.

What formulations are protected by glycopyrrolate oral solution patents?

The active ingredient is an established small molecule, so the principal intellectual-property value is more likely to reside in product-specific formulation, dosing, delivery and manufacturing claims than in composition-of-matter protection.

Potential claim categories include:

• Glycopyrrolate concentration ranges
• Buffered aqueous solutions
• Specific preservative combinations
• Taste-masked formulations
• Low-volume pediatric dosing
• Stability after opening
• Unit-dose or multidose packaging
• Oral syringe-based administration
• Methods for treating chronic drooling
• Patient-specific titration regimens

Cuvposa’s original regulatory exclusivity was limited by the age of the active ingredient. Its commercial protection depended more heavily on product-specific patents, regulatory exclusivity and execution than on new chemical entity protection. Patent status should be assessed through the current FDA Orange Book, USPTO records and litigation databases rather than inferred from the age of glycopyrrolate [2,4].

When does glycopyrrolate oral solution lose exclusivity?

The product’s New Chemical Entity exclusivity is not the principal barrier to generic competition because glycopyrrolate predates Cuvposa by decades. Cuvposa received approval in 2010, and any associated three-year approval exclusivity would have expired after the relevant clinical investigation period, subject to FDA listing and exclusivity records [2].

The practical loss-of-exclusivity analysis depends on four elements:

Exclusivity element	Commercial relevance
NCE exclusivity	Not expected to protect glycopyrrolate as a new active ingredient
Pediatric exclusivity	Could extend listed protections if awarded for qualifying studies
Formulation patents	May delay or complicate specific generic approaches
Method-of-use patents	May affect labeled indication or carve-out strategy

Generic entry may still occur if an ANDA applicant can certify that listed patents are expired, invalid, unenforceable or not infringed. A Paragraph IV certification can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework [5].

What is the Orange Book status of Cuvposa?

Cuvposa is the relevant reference-listed drug for glycopyrrolate oral solution. The Orange Book provides the authoritative record for approved products, therapeutic equivalence evaluations and any listed patents or exclusivity periods [2].

For market-entry analysis, the critical checks are:

1. Whether Cuvposa remains the reference-listed drug for the targeted strength.
2. Whether any patents remain listed against the oral solution.
3. Whether listed patents cover the formulation, method of use or both.
4. Whether generic applicants have submitted Paragraph IV certifications.
5. Whether FDA has awarded pediatric or other regulatory exclusivity.
6. Whether an authorized generic or licensed equivalent is commercially available.

Patent listings can change, and product-specific status must be reviewed against the current Orange Book record.

Which companies are challenging glycopyrrolate oral solution?

Competition is expected to come primarily from generic pharmaceutical companies rather than biosimilar developers. Glycopyrrolate oral solution is a conventional small-molecule product and does not qualify for the biosimilar pathway.

Likely competitor categories include:

• ANDA applicants seeking pharmaceutical equivalence to Cuvposa
• Manufacturers of compounded glycopyrrolate liquids
• Specialty pharmacies supplying extemporaneous formulations
• Companies offering alternative glycopyrrolate dosage forms
• Pediatric drug-delivery companies providing oral syringes and adherence systems

Compounded products may compete on price and availability but generally lack the same FDA-approved labeling, quality controls and commercial consistency as an approved product. Their role is most relevant during shortages, insurance restrictions or when a patient needs a concentration not commercially available.

What generic entry risks exist for glycopyrrolate oral solution?

Generic entry risk is structurally high because the molecule is old, the dosage form is relatively straightforward and the target product is an aqueous oral liquid. The main barriers are formulation performance and regulatory execution rather than active-ingredient complexity.

High-risk areas for an incumbent

• Price erosion after multiple ANDA approvals
• Substitution by pharmacy benefit managers
• Payer preference for lower-cost liquid products
• Hospital and specialty-pharmacy purchasing pressure
• Compounding substitution when commercial supply is constrained
• Loss of differentiation if all products use similar flavor and dosing systems

Potential generic development barriers

• Taste and palatability
• Preservative efficacy
• Stability after opening
• Accurate delivery at low pediatric doses
• Container and oral-syringe compatibility
• Demonstration of bioequivalence for an oral solution
• Labeling restrictions related to the approved pediatric indication

An oral solution can be easier to develop than a solid dosage form because dissolution is not a major bioequivalence variable. The formulation still must match critical quality attributes and satisfy FDA requirements for inactive ingredients, stability and microbiological quality.

How strong is the patent estate for glycopyrrolate oral solution?

The patent estate is likely moderate to weak at the active-ingredient level and potentially stronger at the product level. The commercial value of any remaining rights would depend on claim breadth, expiration dates, enforceability and whether a generic can design around the claims.

Patent layer	Expected strength
Glycopyrrolate composition of matter	Low, because the active ingredient is longstanding
Basic aqueous solution	Low to moderate
Specific excipient combination	Moderate if supported by unexpected stability or tolerability data
Taste-masking technology	Moderate, depending on claim scope
Delivery device integration	Moderate to strong where claims are narrow and product-specific
Pediatric dosing method	Variable and vulnerable to label carve-outs
Manufacturing process	Moderate if it solves a reproducible stability or impurity problem

The strongest new filing opportunities would involve measurable technical advantages, such as improved stability, lower preservative exposure, reduced dosing error or better acceptance in children with dysphagia.

What commercial opportunities exist for excipient innovation?

Preservative-reduced or preservative-free products

A preservative-reduced product could target children with chronic exposure concerns, patients with excipient sensitivities and caregivers seeking a simpler formulation. The commercial model would require packaging that limits repeated contamination, such as unit-dose sachets, ampoules or a validated metered dispenser.

Improved taste and adherence

A well-characterized flavor platform could support premium pricing if clinical or real-world data show higher persistence or fewer missed doses. The target market includes children with cerebral palsy, developmental disabilities, autism-spectrum sensory sensitivities and feeding disorders.

High-concentration formulations

A higher concentration could reduce administration volume. Cuvposa is commonly supplied at 1 mg/5 mL. A more concentrated product could be commercially useful when the prescribed dose is large, but it would require careful evaluation of taste, dosing-device accuracy and accidental overdose risk.

Unit-dose and institutional packaging

Unit-dose packaging can reduce contamination risk and dosing variability in schools, long-term-care facilities and pediatric clinics. It may also support preservative reduction. The tradeoff is higher packaging cost and increased logistics complexity.

Integrated oral-syringe systems

An oral solution packaged with a dose-specific syringe, bottle adapter and clear graduated markings can reduce dosing errors. Device integration may create a stronger commercial position than excipient changes alone.

Customized flavor platforms

Multiple flavor options can improve patient choice, but each flavor may require separate stability, preservative and packaging assessments. A modular flavor strategy is more practical than launching a large number of variants at once.

How does glycopyrrolate oral solution compare with competing treatments?

Glycopyrrolate competes with other anticholinergic therapies and procedural approaches for sialorrhea.

Therapy	Dosage form	Main commercial advantage	Main limitation
Glycopyrrolate oral solution	Liquid	Pediatric titration and flexible dosing	Anticholinergic adverse effects and taste
Sublingual atropine	Drops	Low-volume administration	Off-label use and variable dosing
Scopolamine transdermal system	Patch	Less frequent administration	Patch tolerability and systemic effects
Botulinum toxin injections	Injectable	Local treatment option	Procedure-based care and repeat injections
Salivary gland surgery	Surgical	Potentially durable effect	Invasive and irreversible risks

Glycopyrrolate’s strongest commercial position is in children who need titratable oral treatment and cannot reliably swallow tablets. Its primary competitive weakness is the burden of daily administration and systemic anticholinergic effects.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

1. Excipient technology that improves taste without compromising stability.
2. Metered-dose or unit-dose delivery systems.
3. Pediatric adherence platforms connected to caregiver dosing records.
4. Regional commercialization rights in markets where pediatric sialorrhea treatment is underdeveloped.

A licensee would likely prioritize technology that can be applied to multiple pediatric oral liquids rather than a single glycopyrrolate product. A platform excipient or device patent can support broader revenue than a narrow formulation claim.

What revenue exposure does glycopyrrolate oral solution create?

Revenue exposure is concentrated in a niche pediatric market. The product is not a high-volume primary-care medicine, but it can generate durable specialty revenue because patients may require long-term treatment and dosage titration.

Commercial risks include:

• Generic price compression
• Small eligible patient population
• Reimbursement restrictions
• Caregiver administration burden
• Competition from compounded liquids
• Adverse-effect-driven discontinuation
• Limited indication expansion without new clinical evidence

A differentiated product could defend pricing through lower dosing volume, better adherence, reduced contamination risk or improved tolerability. A formulation change without demonstrated patient or caregiver value would be less likely to command a premium.

What manufacturing and IP barriers affect market entry?

Manufacturing is technically manageable but requires tight control of liquid-product risks. Important controls include:

• Homogeneous glycopyrrolate concentration
• pH control
• Preservative distribution
• Microbial limits
• Flavor uniformity
• Bottle and closure compatibility
• Accurate fill volume
• Stability after repeated opening
• Compatibility with oral syringes

The most defensible manufacturing claims would relate to impurity control, extended in-use stability, improved preservative performance or a specialized filling and packaging process. Generic manufacturers can often design around narrow excipient claims by changing sweeteners, flavors, preservatives or packaging.

Key Takeaways

• Glycopyrrolate oral solution is an FDA-approved pediatric small-molecule product, with Cuvposa as the reference product.
• The active ingredient is old, so commercial protection depends mainly on formulation, delivery, manufacturing and method-of-use rights.
• Taste masking, preservative strategy, low-volume dosing and oral-syringe accuracy are the leading excipient-driven opportunities.
• Biosimilar risk is irrelevant; the competitive threat is from ANDA-approved generics and compounded liquids.
• Preservative-reduced, unit-dose and metered-dose products offer the clearest differentiation paths.
• A strong product patent should claim a measurable technical or clinical benefit, not merely a routine excipient substitution.
• Current Orange Book listings, patent claims and Paragraph IV activity control the final generic-entry assessment.

FAQs

Can glycopyrrolate oral solution be formulated without parabens?

Yes. A preservative-free or paraben-free formulation is technically possible, but it requires an alternative microbial-control strategy, compatible packaging and validated in-use stability.

Is a higher-strength glycopyrrolate oral solution commercially attractive?

Potentially. A higher concentration could reduce administration volume, but the product would face greater taste, dosing-error and accidental-ingestion risks.

Can an excipient change support a new glycopyrrolate patent?

Yes, if the formulation produces a patentable technical effect, such as improved stability, reduced degradation, superior taste masking or extended in-use shelf life.

Are compounded glycopyrrolate liquids substitutes for FDA-approved products?

They can be practical substitutes in some settings, but they generally do not provide the same approved labeling, commercial consistency or standardized quality controls.

What is the most defensible product-differentiation strategy?

A combined platform using improved palatability, a low-volume dose, an integrated oral syringe and contamination-limiting packaging offers stronger commercial differentiation than a flavor change alone.

References

1. U.S. Food and Drug Administration. (2023). Cuvposa (glycopyrrolate) oral solution prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. National Library of Medicine. (2024). DailyMed: Glycopyrrolate oral solution labeling.
4. United States Patent and Trademark Office. (2024). Patent Center and Patent Public Search.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity: Questions and answers.